Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association
出版年份 2021 全文链接
标题
Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association
作者
关键词
-
出版物
Circulation-Genomic and Precision Medicine
Volume -, Issue -, Pages -
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2021-04-26
DOI
10.1161/hcg.0000000000000082
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
- (2020) G. Curigliano et al. ANNALS OF ONCOLOGY
- Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer
- (2020) Farzin Khosrow-Khavar et al. CIRCULATION
- Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2020) Cora N. Sternberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
- (2020) Neal D. Shore et al. NEW ENGLAND JOURNAL OF MEDICINE
- NCCN Guidelines Insights: Survivorship, Version 2.2020
- (2020) Crystal S. Denlinger et al. Journal of the National Comprehensive Cancer Network
- Call to Action: Structural Racism as a Fundamental Driver of Health Disparities: A Presidential Advisory From the American Heart Association
- (2020) Keith Churchwell et al. CIRCULATION
- Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors
- (2019) Xiaoqing Xu et al. BREAST CANCER RESEARCH AND TREATMENT
- Therapeutic advances in hormone-dependent cancers: focus on prostate, breast, and ovarian cancers
- (2019) Michael Ulm et al. Endocrine Connections
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Left Ventricular Speckle Tracking Echocardiography Changes Among Early-stage Breast Cancer Patients Three Years After Radiotherapy
- (2019) SUVI SIRKKU TUOHINEN et al. ANTICANCER RESEARCH
- Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and GnRH-antagonist among patients with advanced prostate-cancer and pre-existing cardiovascular disease
- (2019) David Margel et al. JOURNAL OF UROLOGY
- Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities
- (2019) Grace Lu-Yao et al. EUROPEAN UROLOGY
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
- (2018) G N Hortobagyi et al. ANNALS OF ONCOLOGY
- Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association
- (2018) Laxmi S. Mehta et al. CIRCULATION
- The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer
- (2018) Roberto Iacovelli et al. Clinical Genitourinary Cancer
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
- (2018) Dennis J. Slamon et al. JOURNAL OF CLINICAL ONCOLOGY
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
- (2018) Debu Tripathy et al. LANCET ONCOLOGY
- Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
- (2018) Simon Linder et al. ENDOCRINE-RELATED CANCER
- Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population‐based study
- (2018) Sailaja Kamaraju et al. CLINICAL CARDIOLOGY
- Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review
- (2018) Anthony Matthews et al. BMJ-British Medical Journal
- Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis
- (2017) Hadar Goldvaser et al. JNCI-Journal of the National Cancer Institute
- Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA‐3 Results
- (2017) Sibylle Loibl et al. ONCOLOGIST
- Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis
- (2017) Hadar Goldvaser et al. JNCI-Journal of the National Cancer Institute
- Cardiotoxicity of Aromatase Inhibitors and Tamoxifen in Post-Menopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- (2016) F. Khosrow-Khavar et al. ANNALS OF ONCOLOGY
- Cardiovascular Health among Black and White Breast Cancer Patients Initiating Aromatase Inhibitor Therapy
- (2016) Lisa Gallicchio et al. Breast Journal
- Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer
- (2016) Nirmanmoh Bhatia et al. CIRCULATION
- Cardiovascular side effects of small molecule therapies for cancer: Table 1
- (2016) Shawn C. Pun et al. EUROPEAN HEART JOURNAL
- The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer
- (2016) Husam Abdel-Qadir et al. EUROPEAN JOURNAL OF CANCER
- Safety of mTOR inhibitors in breast cancer
- (2016) Hana Študentová et al. Expert Opinion On Drug Safety
- Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
- (2016) John F R Robertson et al. LANCET
- Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer
- (2016) Lucie-Marie Scailteux et al. MEDICINE
- Cardiovascular Disease After Aromatase Inhibitor Use
- (2016) Reina Haque et al. JAMA Oncology
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study
- (2015) Giorgio Gandaglia et al. Clinical Genitourinary Cancer
- Risk and Timing of Cardiovascular Disease After Androgen-Deprivation Therapy in Men With Prostate Cancer
- (2015) Sean O'Farrell et al. JOURNAL OF CLINICAL ONCOLOGY
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
- (2015) LANCET
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
- (2015) Prudence A. Francis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular risk with androgen deprivation therapy for prostate cancer: Potential mechanisms
- (2015) Åsa Tivesten et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
- (2014) M. Piccart et al. ANNALS OF ONCOLOGY
- Racial differences in breast cancer, cardiovascular disease, and all-cause mortality among women with ductal carcinoma in situ of the breast
- (2014) Amy Berkman et al. BREAST CANCER RESEARCH AND TREATMENT
- ABCDE Steps to Prevent Heart Disease in Breast Cancer Survivors
- (2014) Kamaneh Montazeri et al. CIRCULATION
- Androgen Deprivation Therapy for Prostate Cancer Is Associated with Cardiovascular Morbidity and Mortality: A Meta-Analysis of Population-Based Observational Studies
- (2014) Jinsheng Zhao et al. PLoS One
- Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist
- (2013) Peter C. Albertsen et al. EUROPEAN UROLOGY
- Association between tamoxifen treatment and diabetes
- (2011) Lorraine L. Lipscombe et al. CANCER
- Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer
- (2011) Paul L. Nguyen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study
- (2011) Marco Colleoni et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
- (2011) Cornelis JH van de Velde et al. LANCET
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum
- (2010) P. E. Lønning ANNALS OF ONCOLOGY
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
- (2010) Jack Cuzick et al. LANCET ONCOLOGY
- Mechanisms of Estrogen-Induced Venous Thromboembolism
- (2010) Svetlana N. Tchaikovski et al. THROMBOSIS RESEARCH
- Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism
- (2009) Rohini K. Hernandez et al. CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now